Topic: idiopathic pulmonary fibrosis
In Boehringer Ingelheim’s first branded TV ad for its idiopathic pulmonary fibrosis treatment Ofev, the spotlight is not on the patient, but on a loved one.
A year after tapping a former Yankees star for its "Breathless" push, Boehringer Ingelheim had another surprise for baseball fans this opening day.
Boehringer Ingelheim wants to move its drug nintedanib into the scleroderma market. Meanwhile, it’s working to expand awareness of the disease, too.
This week, both IPF drugmakers upped the ante with positive new data for their contenders at the American Thoracic Society's annual meeting.